Clinical Trial Update: A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function [Phase 1]

View source ↗

Summary

A Phase 1, non-randomized, open-label pharmacokinetics and safety study of Dimebon (latrepirdine) in subjects with severely impaired and normal renal function h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Huntington Disease

Drugs mentioned

• Dimebon (latrepirdine)

Snippet

Sponsor: Pfizer | Conditions: Alzheimer's Disease, Huntington's Disease | Phase 1 | Status: COMPLETED